TD Asset Management Inc Sells 19,379 Shares of argenex SE $ARGX

TD Asset Management Inc lessened its stake in shares of argenex SE (NASDAQ:ARGX) by 16.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 101,523 shares of the company’s stock after selling 19,379 shares during the period. TD Asset Management Inc owned 0.16% of argenex worth $85,376,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Abound Wealth Management boosted its holdings in shares of argenex by 3,200.0% during the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock valued at $28,000 after purchasing an additional 32 shares during the last quarter. Sound Income Strategies LLC purchased a new stake in shares of argenex during the 4th quarter valued at about $28,000. Ameriflex Group Inc. purchased a new stake in shares of argenex during the 3rd quarter valued at about $32,000. Sunbelt Securities Inc. purchased a new stake in shares of argenex during the 3rd quarter valued at about $36,000. Finally, Aventura Private Wealth LLC purchased a new stake in shares of argenex during the 4th quarter valued at about $38,000. Institutional investors own 60.32% of the company’s stock.

argenex Price Performance

argenex stock opened at $842.27 on Friday. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62. The firm has a market capitalization of $52.38 billion, a P/E ratio of 37.50, a price-to-earnings-growth ratio of 1.24 and a beta of 0.47. The company’s 50-day moving average is $791.02 and its 200 day moving average is $812.87.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. The company had revenue of $1.31 billion for the quarter. Research analysts anticipate that argenex SE will post 26.19 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. HC Wainwright upped their target price on shares of argenex from $915.00 to $940.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Deutsche Bank Aktiengesellschaft upgraded shares of argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. Citizens Jmp upped their target price on shares of argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a research report on Friday, February 27th. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a research report on Monday, April 20th. Finally, Wells Fargo & Company upped their target price on shares of argenex from $1,260.00 to $1,291.00 and gave the company an “overweight” rating in a research report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,019.50.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.